Prescribing information


Quality of life outcomes with KISQALI from three phase III trials.

KISQALI was demonstrated to improve or maintain quality of life in all three clinical trials1–4

KISQALI + endocrine therapy can help give patients quality time, improving or maintaining measures such as pain, fatigue and gastrointestinal symptoms.1–4


Table summarising the quality of life results with KISQALI vs placebo in the MONALEESA-7, MONALEESA-3 and MONALEESA-2 trials

AI, aromatase inhibitor; EOT, end of treatment; QoL, quality of life; TTD, time to deterioration.


*KISQALI is not recommended to be used in combination with tamoxifen.5

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.5


  1. Beck JT, et al. P6-18-14. Presented at 2018 San Antonio Breast Cancer Symposium, 4–8 December 2018, San Antonio, Texas, USA.
  2. Harbeck N, et al. Abstract 2910. Presented at ESMO 2018 Congress, 19–23 October 2018, Munich, Germany.
  3. Verma S, et al. Breast Cancer Res Treat 2018;170(3):535–545.
  4. Fasching PA, et al. Presented at European Society for Medical Oncology Congress, 19–23 October 2018, Munich, Germany.
  5. KISQALI® (ribociclib) Summary of Product Characteristics.
HCP20-C013 July 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]